5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

Core Insights - 5AM Venture Management, LLC has completely liquidated its position in Viking Therapeutics, resulting in a net position change of approximately $5.02 million [2][3][7] Company Overview - Viking Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for metabolic and endocrine diseases [9] - The company has a pipeline of orally available drug candidates aimed at addressing significant unmet medical needs, including non-alcoholic steatohepatitis and rare genetic disorders [9] Financial Performance - As of November 18, 2025, shares of Viking Therapeutics were priced at $38.00, reflecting a year-to-date performance decline of 5.6% [4][5] - The company's stock has underperformed the S&P 500 by 18.7 percentage points during the same period [4] Investment Position - Following the sale, Viking Therapeutics now represents 0% of 5AM Venture Management's reportable assets under management (AUM) [4][7] - Previously, Viking Therapeutics accounted for approximately 1.9% of the fund's AUM [3][7] Market Context - The exit from Viking Therapeutics by 5AM Venture Management is viewed as a rebalancing strategy rather than a lack of confidence in the company's scientific endeavors [10] - Viking Therapeutics operates in a market characterized by significant patient needs, but the path to commercialization is often lengthy and fraught with challenges [11][12]